The inhibitory potential of aminopropionitriles towards lysyl- oxidase was investigated both in-vivo and in-vitro. The compounds tested included beta-aminopropionitrile (151188) (BAPN), 3,3'- dimethylaminopropionitrile (DMAPN), 3,3'-iminodipropionitrile (111944) (IDPN), and monomethylaminopropionitrile (MMAPN). Lysyl- oxidase inhibition was determined in-vitro by incubating various concentrations of each compound with supernatant obtained from chick embryo leg bones and radiolabeled chick embryo aorta substrate. In- vivo inhibition experiments were conducted on male Sprague-Dawley- rats administered 400mg/kg BAPN, 100mg/kg MMAPN, 250mg/kg DMAPN, or 300mg/kg IDPN by intraperitoneal injection for 4 days. A second group was pretreated with pargyline before receiving the same dosage regimen. Incubation of BAPN, IDPN, and MMAPN with chick embryo leg bone supernatant resulted in inhibition of the lysyl-oxidase catalyzed release of tritium from labeled aortic substrate. DMAPN was a significantly less potent inhibitor of lysyl-oxidase. BAPN and IDPN induced irreversible inhibition of lysyl-oxidase but DMAPN and MMAPN did not. Rats treated with BAPN exhibited a significant decrease in lysyl-oxidase activity compared to controls. Pretreatment with pargyline increased slightly the BAPN induced inhibition of lysyl-oxidase. Animals treated with IDPN had a small but insignificant decrease in lysyl-oxidase activity. The authors conclude that the presence of a primary amino functional group in aminopropionitriles is not a condition necessary for inhibition of lysyl-oxidase. Additionally, reversible and irreversible inhibition mechanisms may be associated with osteolathyric changes induced by IDPN exposure.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.